![]() ![]() ![]() patients ≤ 74 years median OS 8.5 months, 95% CI 0–20.5 months, p-value: 0.88) and progression-free survival (PFS, patients ≤ 74 years median PFS 5.1 months, 95% CI 3.8–6.4 months vs. In our series, we did not find any correlation with age for both overall survival (OS, patients ≤ 74 years median OS 11.4 months, 95% CI 7.2–15.7 months vs. (a) Overall survival (OS) and (b) progression-free survival (PFS) of metastatic non-small-cell lung cancer (mNSCLC) patients under treatment with nivolumab or atezolizumab divided into two age-related groups: age 75 years (green).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |